( SAN DIEGO--(BUSINESS WIRE)--Jul 2 2007...)Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth,Conference and Attend Pacific Growth Equities Conference,Health

SAN DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Metabasis Therapeutics (NASDAQ:MBRX), a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of metabolic and liver diseases by targeting the liver and liver pathways, announced today that John Beck, senior vice president of finance and chief financial officer of Metabasis will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference at the Mandarin Oriental Hotel in New York, NY. Mr. Beck is scheduled to present on Wednesday, July 11, 2007 at 9:30 a.m. Eastern Time, and is expected to provide an overview of the Company's progress and discuss product candidates in clinical development. Metabasis will also be participating in the Pacific Growth Equities Cardiology & Metabolic Diseases Conference, scheduled for Thursday, July 12, 2007 at the Grand Hyatt Hotel in New York, NY.

To access the live audio broadcast and the subsequent archived audio recording of the presentation, please log onto the Company's website at www.mbasis.com under the "Investors" section. The audio recording and presentation will be archived there for 30 days following the live presentation. Please connect to Metabasis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About Metabasis (www.mbasis.com):

Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread and costly chronic diseases involving pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include major metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver dise
'"/>

Page: 1 2
Related medicine technology :

1. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
2. Metabasis Therapeutics to Present Poster at American Association for Cancer Research
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference